AZD 0022
Alternative Names: AZD-0022Latest Information Update: 26 Jun 2025
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 18 Oct 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Australia, USA (PO) (NCT06599502)
- 18 Oct 2024 Phase-I/II clinical trials in Solid tumours (Monotherapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia, USA (PO) (NCT06599502)